{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:40:07Z","timestamp":1761864007728},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1684\/bdc.2011.1483","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T20:07:50Z","timestamp":1565726870000},"page":"371-380","source":"Crossref","is-referenced-by-count":4,"title":["Gestion des chimioth\u00e9rapies chez les patients h\u00e9modialys\u00e9s"],"prefix":"10.1016","volume":"99","author":[{"given":"Nicolas","family":"Janus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Launay-Vacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilbert","family":"Deray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Thyss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliette","family":"Thariat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2011.1483_bib0005","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22904","article-title":"Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study","volume":"110","author":"Launay-Vacher","year":"2007","journal-title":"Cancer"},{"key":"10.1684\/bdc.2011.1483_bib0010","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.semnephrol.2010.09.003","article-title":"Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group","volume":"30","author":"Launay-Vacher","year":"2010","journal-title":"Semin Nephrol"},{"key":"10.1684\/bdc.2011.1483_bib0015","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000180813","article-title":"Increased incidence of malignancy in chronic renal failure","volume":"18","author":"Sutherland","year":"1977","journal-title":"Nephron"},{"key":"10.1684\/bdc.2011.1483_bib0020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1023\/A:1014489911153","article-title":"Increased incidence of neoplasia in chronic renal failure (20-year experience)","volume":"33","author":"Cengiz","year":"2002","journal-title":"Int Urol Nephrol"},{"key":"10.1684\/bdc.2011.1483_bib0025","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(75)91684-0","article-title":"Increased incidence of malignancy during chronic renal failure","volume":"1","author":"Matas","year":"1975","journal-title":"Lancet"},{"key":"10.1684\/bdc.2011.1483_bib0030","first-page":"597","article-title":"Pharmacokinetic changes in renal failure","volume":"30","author":"Launay-Vacher","year":"2001","journal-title":"Presse Med"},{"key":"10.1684\/bdc.2011.1483_bib0035","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00228-009-0678-8","article-title":"Pharmacokinetics and dosage adjustment in patients with renal dysfunction","volume":"65","author":"Verbeeck","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1684\/bdc.2011.1483_bib0040","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000086591","article-title":"FHD: an index to evaluate drug elimination by hemodialysis","volume":"25","author":"Launay-Vacher","year":"2005","journal-title":"Am J Nephrol"},{"key":"10.1684\/bdc.2011.1483_bib0045","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s004010050482","article-title":"Metabolites of 5-fluorouracil, alpha-fluoro-beta-alanine and fluoroacetic acid directly injure myelinated fibers in tissue culture","volume":"92","author":"Akiba","year":"1996","journal-title":"Acta Neuropathol"},{"key":"10.1684\/bdc.2011.1483_bib0050","first-page":"2203","article-title":"Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile","volume":"47","author":"Heggie","year":"1987","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2011.1483_bib0055","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1053\/ajkd.2002.30584","article-title":"Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis","volume":"39","author":"Rengelshausen","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1684\/bdc.2011.1483_bib0060","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/01.ftd.0000183384.89275.f4","article-title":"Effect of hemodialysis on the metabolic clearance of 5-fluorouracil in a patient with end-stage renal failure","volume":"27","author":"Gusella","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.1684\/bdc.2011.1483_bib0065","first-page":"1482","article-title":"Successful treatment with 5-fluorouracil and cis-dichlorodiammineplatinum combined with 60 Gy of radiation in a case of advanced esophageal cancer complicated with chronic renal failure treated with hemodialysis","volume":"105","author":"Arai","year":"2008","journal-title":"Nippon Shokakibyo Gakkai Zasshi"},{"key":"10.1684\/bdc.2011.1483_bib0070","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/jjco\/hyp176","article-title":"Drug monitoring during FOLFOX6 therapy in a rectal cancer patient on chronic hemodialysis","volume":"40","author":"Watayo","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"10.1684\/bdc.2011.1483_bib0075","first-page":"449","article-title":"5-FU\/l-LV therapy is useful for hemodialysis patients with advanced gastric cancer","volume":"38","author":"Saito","year":"2011","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1684\/bdc.2011.1483_bib0080","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/bjc.1998.12","article-title":"The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate","volume":"77","author":"Arellano","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1684\/bdc.2011.1483_bib0085","series-title":"GPR Anticanc\u00e9reux. Guide de prescription des m\u00e9dicaments chez le patient insuffisant r\u00e9nal","author":"Launay-Vacher","year":"2008"},{"key":"10.1684\/bdc.2011.1483_bib0090","unstructured":"SiteGPR. Available at: http:\/\/www.sitegpr.com\/ (consult\u00e9 28 avril 2011)."},{"key":"10.1684\/bdc.2011.1483_bib0095","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1158\/1078-0432.CCR-03-0237","article-title":"Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy","volume":"10","author":"Chung","year":"2004","journal-title":"Clin. Cancer Res"},{"key":"10.1684\/bdc.2011.1483_bib0100","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2165\/00003495-200767040-00010","article-title":"Capecitabine: in advanced gastric or oesophagogastric cancer","volume":"67","author":"Dhillon","year":"2007","journal-title":"Drugs"},{"key":"10.1684\/bdc.2011.1483_bib0105","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00280-001-0408-0","article-title":"Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients","volume":"49","author":"Poole","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1684\/bdc.2011.1483_bib0110","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1483_bib0115","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1525-1438.2007.00847.x","article-title":"Systemic anticancer therapy in gynecological cancer patients with renal dysfunction","volume":"17","author":"Li","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1684\/bdc.2011.1483_bib0120","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000187794","article-title":"Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency","volume":"66","author":"Chatelut","year":"1994","journal-title":"Nephron"},{"key":"10.1684\/bdc.2011.1483_bib0125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0305-7372(79)80057-2","article-title":"Cisplatin (cis-diamminedichloroplatinum II)","volume":"6","author":"Prestayko","year":"1979","journal-title":"Cancer Treat Rev"},{"key":"10.1684\/bdc.2011.1483_bib0130","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3109\/07357909109039874","article-title":"Pharmacokinetics of cis-diammine-dichlor-platin in a hemodialysis patient","volume":"9","author":"Tanabe","year":"1991","journal-title":"Cancer Invest"},{"key":"10.1684\/bdc.2011.1483_bib0135","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00007691-199504000-00018","article-title":"Plasma platinum elimination in a hemodialysis patient treated with cisplatin","volume":"17","author":"Gorodetsky","year":"1995","journal-title":"Ther Drug Monit"},{"key":"10.1684\/bdc.2011.1483_bib0140","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1159\/000065582","article-title":"Full-dose chemotherapy for esophageal cancer patient under hemodialysis","volume":"92","author":"Kurisu","year":"2002","journal-title":"Nephron"},{"key":"10.1684\/bdc.2011.1483_bib0145","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200544110-00003","article-title":"Clinical pharmacokinetics of cyclophosphamide","volume":"44","author":"de Jonge","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1684\/bdc.2011.1483_bib0150","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1046\/j.1523-1755.2002.00279.x","article-title":"Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency","volume":"61","author":"Haubitz","year":"2002","journal-title":"Kidney Int"},{"key":"10.1684\/bdc.2011.1483_bib0155","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/BF00548589","article-title":"Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites","volume":"19","author":"Juma","year":"1981","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1684\/bdc.2011.1483_bib0160","first-page":"1037","article-title":"Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion","volume":"53","author":"Extra","year":"1993","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2011.1483_bib0165","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000092903","article-title":"Docetaxel pharmacokinetics with pre- and post-dialysis administration in a hemodyalized patient","volume":"52","author":"Mencoboni","year":"2006","journal-title":"Chemotherapy"},{"key":"10.1684\/bdc.2011.1483_bib0170","first-page":"987","article-title":"Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes","volume":"54","author":"Gabizon","year":"1994","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2011.1483_bib0175","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/BF00686499","article-title":"Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis","volume":"33","author":"Yoshida","year":"1994","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1684\/bdc.2011.1483_bib0180","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF00180192","article-title":"Pharmacokinetics of 4\u2032-epi-doxorubicin in man","volume":"1","author":"Weenen","year":"1983","journal-title":"Invest New Drugs"},{"key":"10.1684\/bdc.2011.1483_bib0185","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/030089160609200421","article-title":"Safety of epirubicin adjuvant chemotherapy in a breast cancer patient with chronic renal failure undergoing hemodialytic treatment","volume":"92","author":"Gori","year":"2006","journal-title":"Tumori"},{"key":"10.1684\/bdc.2011.1483_bib0190","first-page":"379","article-title":"Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients","volume":"44","author":"Hande","year":"1984","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2011.1483_bib0195","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/sj.bjc.6600687","article-title":"Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer","volume":"88","author":"Watanabe","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1684\/bdc.2011.1483_bib0200","first-page":"1279","article-title":"Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient","volume":"69","author":"Holthuis","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"10.1684\/bdc.2011.1483_bib0205","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1996.14.1.257","article-title":"Predicting etoposide toxicity: relationship to organ function and protein binding","volume":"14","author":"Joel","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1483_bib0210","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/annonc\/mdh008","article-title":"Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis","volume":"15","author":"Inoue","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2011.1483_bib0215","first-page":"2566","article-title":"Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function","volume":"46","author":"D\u2019Incalci","year":"1986","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2011.1483_bib0220","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","article-title":"A phase I clinical, plasma, and cellular pharmacology study of gemcitabine","volume":"9","author":"Abbruzzese","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1483_bib0225","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jjco\/hym171","article-title":"Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer","volume":"38","author":"Masumori","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"10.1684\/bdc.2011.1483_bib0230","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00280-003-0574-3","article-title":"Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment","volume":"51","author":"Kiani","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1684\/bdc.2011.1483_bib0235","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1749-6632.2000.tb07038.x","article-title":"Pharmacokinetics of orally administered camptothecins","volume":"922","author":"Gupta","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"10.1684\/bdc.2011.1483_bib0240","first-page":"60","article-title":"Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure","volume":"25","author":"Stemmler","year":"2002","journal-title":"Onkologie"},{"key":"10.1684\/bdc.2011.1483_bib0245","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/CAD.0b013e32811d69cb","article-title":"Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered","volume":"18","author":"V\u00e9nat-Bouvet","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1684\/bdc.2011.1483_bib0250","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/annonc\/mdp598","article-title":"Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients","volume":"21","author":"Janus","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2011.1483_bib0255","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1200\/JCO.2003.11.015","article-title":"Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study","volume":"21","author":"Takimoto","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1483_bib0260","first-page":"673","article-title":"Modified FOLFOX6 in a patient on hemodialysis with metastatic colorectal cancer","volume":"35","author":"Matoba","year":"2008","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1684\/bdc.2011.1483_bib0265","first-page":"1299","article-title":"FOLFOX 4 in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure","volume":"34","author":"Ohnishi","year":"2007","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1684\/bdc.2011.1483_bib0270","first-page":"1379","article-title":"The pharmacokinetics and safety of oxaliplatin in a hemodialysis patient treated with mFOLFOX6 therapy","volume":"36","author":"Fujita","year":"2009","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1684\/bdc.2011.1483_bib0275","doi-asserted-by":"crossref","unstructured":"Horimatsu T, Miyamoto S, Morita S, et al. Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. Cancer Chemother Pharmacol 2011; Available at: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21499694 (consult\u00e9 14 juin 2011).","DOI":"10.1007\/s00280-011-1633-9"},{"key":"10.1684\/bdc.2011.1483_bib0280","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/jjco\/hym044","article-title":"Hepatic arterial infusion of oxaliplatin for a patient with hepatic metastases from colon cancer undergoing hemodialysis","volume":"37","author":"Shitara","year":"2007","journal-title":"Jpn J Clin Oncol"},{"key":"10.1684\/bdc.2011.1483_bib0285","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s002800050868","article-title":"Pharmacokinetics of paclitaxel in an anephric patient","volume":"43","author":"Woo","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1684\/bdc.2011.1483_bib0290","first-page":"437","article-title":"Pharmacokinetic analysis of paclitaxel and carboplatin in a patient with advanced ovarian cancer during hemodialysis \u2013 case report","volume":"27","author":"Yokoyama","year":"2006","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1684\/bdc.2011.1483_bib0295","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1525-1438.2007.01048.x","article-title":"High dose single-agent paclitaxel in a hemodialysis patient with advanced ovarian cancer: a case report with pharmacokinetic analysis and review of the literature","volume":"18","author":"Baur","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1684\/bdc.2011.1483_bib0300","first-page":"2061","article-title":"A case of non-small cell lung carcinoma successfully treated with carboplatin and weekly paclitaxel under renal dysfunction","volume":"31","author":"Mori","year":"2004","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1684\/bdc.2011.1483_bib0305","first-page":"21","article-title":"Pharmacokinetics and metabolism of navelbine","volume":"16","author":"Krikorian","year":"1989","journal-title":"Semin Oncol"},{"key":"10.1684\/bdc.2011.1483_bib0310","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nrneph.2009.97","article-title":"Chemotherapy-associated renal dysfunction","volume":"5","author":"Sahni","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"10.1684\/bdc.2011.1483_bib0315","first-page":"e13562","article-title":"Management of systemic anticancer treatment in patients (pts) under chronic dialysis: a raising concern and an emerging population \u2013 preliminary results of the French CANDY (CANcer and DialYsis) study","volume":"29","author":"Thyss","year":"2011","journal-title":"J Clin Oncol 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition)"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115304847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115304847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T16:17:36Z","timestamp":1664122656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115304847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0007455115304847"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2011.1483","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}